BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Futura Medical: Placing to Raise £3.20 Million


3/11/2011 9:18:24 AM

March 11, 2011 -- Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce a Placing by Nomura Code Securities Limited in which gross proceeds of £3.20 million are being raised through the issue of 4,737,402 new ordinary shares of 0.2 pence each in Futura (“New Ordinary Shares”), to new and existing institutional and other investors at a price of 67.50 pence per share. The Placing represents approximately 7% of the Company’s issued share capital.

The £3.07 million net proceeds of the Placing, which is underwritten by Nomura Code Securities Limited, will be used to provide additional working capital; to progress the Company’s earlier stage projects, RAD100 and TPR100-Rx; and to bring new product opportunities developed in-house into the Company’s development pipeline. The Placing strengthens the balance sheet and will assist the Company in its out-licensing negotiations.

The New Ordinary Shares will rank pari passu with the existing ordinary shares of the Company. Application has been made to the London Stock Exchange and it is anticipated that trading of the New Ordinary Shares will commence on AIM at 8:00am on 16 March 2011.

Futura’s total issued share capital following the admission of the New Ordinary Shares will be 72,380,713. The total number of voting rights in the Company will be 72,380,713.

James Barder, Futura’s Chief Executive, said: “We are delighted to have attracted a number of new high quality institutional shareholders alongside existing institutions at such a transformational and exciting time for the Company.”

For any further information please contact:

Futura Medical plc James Barder, Chief Executive Tel: +44 (0) 1483 685 670

mail to: james.barder@futuramedical.com www.futuramedical.com

Nomura Code Securities Limited Phil Walker / Giles Balleny Tel:+44 (0)20 7776 1200

For media enquiries please contact:

Buchanan Communications Mark Court / Jessica Fontaine Tel: +44 (0) 20 7466 5000

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.co.uk


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->